Oura IPO draws 4x oversubscription, targets $15.62 billion valuation
Smart ring maker Oura launched its US IPO roadshow on September 21, 2026, targeting a fully diluted valuation of $15.62 billion. The offering of 50 million shares at $40-$44 each aims to raise up to $2.2 billion. The IPO has received approximately 4x oversubscription, with pricing set for September 29 and trading on Nasdaq under ticker "OURA." Eli Lilly and Dragoneer have indicated interest in purchasing up to $100 million and $300 million of shares respectively. Oura reported $1.21 billion in revenue for the nine months ended June 30, a 74% year-over-year increase.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both agents agree that Oura's $15.6 billion valuation is too high for a hardware company with a niche product.
- They agree that the 73% of shares being sold by insiders is a red flag, not a sign of growth.
- Both see the 4x oversubscription as a sign of a desperate IPO market, not strong investor confidence.
- They agree that Samsung's Galaxy Ring, at $399 with no subscription, is a real competitive threat.
- Both predict the stock will drop within six months after listing, especially when insider lockups expire.
Points of contention
- The Western Agent says the class-action lawsuit over sleep accuracy could destroy Oura's brand and subscription revenue, while the Neutral Agent says it's just a marketing issue that won't hurt the business.
- The Western Agent thinks geopolitical risks like tariffs and currency swings are a big deal for Oura, but the Neutral Agent says those risks are overblown and common for all hardware companies.
- The Neutral Agent believes Oura's subscription model is sticky and defensible, while the Western Agent argues it will collapse if trust in the product is broken.
Blind spots
- Both agents overlooked how Oura's partnership with Eli Lilly could create new revenue streams from drug trials, which might offset hardware risks.
- Neither discussed the potential for Oura to expand into corporate wellness programs or insurance partnerships, which could boost subscription growth.
- They didn't consider that Oura's small form factor might appeal to a growing market of people who want minimal tech, not just watch-haters.
WorldAttention’s read
After a thorough debate, both agents agree that Oura's IPO is overpriced and driven by a desperate market, not solid fundamentals. The main disagreement is over how serious the class-action lawsuit is—the Western Agent sees it as a brand-killer, while the Neutral Agent dismisses it as a legal nuisance. They also clash on geopolitical risks, with the Western Agent stressing them and the Neutral Agent downplaying them. Both missed the potential for Oura to grow through pharma partnerships or corporate deals. In the end, they predict the stock will fall within six months, but for different reasons: the Western Agent blames lawsuits and tariffs, while the Neutral Agent blames basic math and competition from Samsung.
Reporting timeline
Oura IPO Oversubscribed 4x: Is $15 Billion Valuation a Bubble or a Positive Signal?
Wearable device company Oura's IPO has seen strong demand, with orders reaching four times the available shares, pushing pricing toward the upper end of the $40-$44 range. The offering, led by Goldman Sachs and Morgan Stanley, involves 50 million shares and could value Oura at over $150 billion on a fully diluted basis, according to Bloomberg. The company aims for a $156.2 billion valuation ahead of a fall listing. This comes amid a sluggish 2026 IPO market, with several companies delaying plans. Former New York Fed President Bill Dudley warned of stock market bubbles. However, Woofun AI data suggests the high valuation reflects supply-demand mismatches due to liquidity scarcity rather than fundamental investor confidence. Financially, Oura's revenue grew 74% to $1.21 billion over nine months, with paid members doubling to 5 million and net income rising to $60.8 million. However, the company reported a $924.3 million loss attributable to common shareholders, mainly from preferred stock buybacks. The IPO structure is dilutive, with 73% being secondary shares sold by existing shareholders. The revenue mix is hardware-heavy ($974 million from devices vs. $240.5 million from subscriptions), raising questions about its software-like valuation premium. The article concludes that consumer adoption will ultimately determine the company's true value.
Oura's 'AI Ring' IPO Gets 4x Oversubscription, Bucking Market Trend
Smart ring manufacturer Oura has secured approximately 4x oversubscription for its IPO, according to Bloomberg sources, amid a challenging US equity market. The company and existing shareholders are offering 50 million shares at $40-$44 each, aiming to raise up to $2.2 billion. At the top of the range, the company would be valued at $14.1 billion, or about $15 billion fully diluted. Pricing is set for September 29, with trading on the Nasdaq under ticker 'OURA'. The strong demand contrasts with recent IPO postponements by Holtec Nuclear Corp. and Bamboo Insurance Services Inc., which cited market conditions. If completed, Oura's IPO would be the first over $1 billion in nearly three months, serving as a bellwether for the new-issue market. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co., and Jefferies are joint lead underwriters. The company is selling 13.5 million shares, while selling shareholders including Forerunner Ventures and Lifeline Ventures offer 36.5 million shares. Discussions are ongoing and details may change.
Read sourceOura IPO Gets 4x Oversubscription, Defying Market Turmoil and IPO Delays
Smart ring maker Oura has secured approximately 4x oversubscription for its IPO, bucking a turbulent market trend. According to Bloomberg citing sources, underwriters expect to close investor orders by Monday afternoon. Oura and some shareholders are offering 50 million shares at $40-$44 each, aiming to raise up to $2.2 billion. At the high end, the company's market value would reach $14.1 billion, or about $15 billion fully diluted. Pricing is set for September 29, with trading on Nasdaq under 'OURA'. The strong demand contrasts with recent IPO postponements by Holtec Nuclear Corp. and Bamboo Insurance Services Inc. due to market conditions. Of the 50 million shares, Oura is selling 13.5 million, and existing shareholders including Forerunner Ventures and Lifeline Ventures are selling 36.5 million. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co., and Jefferies are joint lead underwriters. Oura and Goldman declined to comment. The deal, if completed, would be the first U.S. IPO over $1 billion since July, serving as a bellwether for the new-issue market.
Show 5 older updatesHide older updates
Oura Smart Ring IPO Roadshow Launches, Targets $2.2 Billion Valuation
Oura launched its initial public offering roadshow on Monday, September 21, 2026, aiming to raise up to $2.2 billion by selling 50 million shares priced between $40 and $44 each. The company will list on the Nasdaq Global Select Market under the ticker 'OURA,' with trading expected to begin next week. Of the 50 million shares, Oura is offering 13.5 million and existing stockholders are selling 36.5 million; Oura will not receive proceeds from the latter. Underwriters have a 30-day option to purchase up to 7.5 million additional shares. The offering targets a fully diluted valuation of $15.62 billion, according to Reuters. Eli Lilly has signaled it may buy up to $100 million worth of shares, and investment firm Dragoneer has expressed interest in acquiring up to $300 million. Lead underwriters are Goldman Sachs, Morgan Stanley, and J.P. Morgan. Oura moved 3.6 million rings in the year through June 30, with revenue hitting $1.21 billion for the nine months ended on that date, a roughly 74% jump year-over-year. By fiscal 2026 end, the company projects its paid membership base will reach approximately 5.7 million, nearly doubling from the prior year. The IPO follows a $900 million late-stage funding round last October that valued Oura at $11 billion. Founded in 2013 in Finland, Oura is now headquartered in San Francisco. The company faces a proposed class-action lawsuit filed in August alleging its ring cannot measure sleep stages with the accuracy claimed in marketing; Oura disputes the allegations. The IPO arrives amid market fragility due to AI trade turbulence, climbing bond yields, and uncertainty over Federal Reserve interest rate policy.
Read sourceOura smart ring IPO roadshow launches, targets $2.2 billion valuation
Oura launched its initial public offering on Monday, aiming to raise up to $2.2 billion by selling 50 million shares at a price range of $40 to $44 each. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol 'OURA,' with trading expected to begin next week. Of the 50 million shares, Oura is offering 13.5 million and existing stockholders are offering the remaining 36.5 million; Oura will not receive proceeds from the shares sold by existing stockholders. The offering targets a fully diluted valuation of $15.62 billion. Eli Lilly has signaled it may buy up to $100 million worth of shares, and investment firm Dragoneer has expressed interest in acquiring up to $300 million worth. Lead underwriters are Goldman Sachs, Morgan Stanley, and J.P. Morgan. According to its IPO prospectus, Oura moved 3.6 million rings in the year through June 30, with revenue hitting $1.21 billion for the nine months ended on that date, a roughly 74% jump from the same period a year earlier. The IPO comes after a late-stage funding round last October brought in $900 million and pushed its valuation to $11 billion. Oura is also contending with a proposed class-action lawsuit filed in August alleging its ring cannot measure sleep stages with the accuracy claimed in marketing; Oura disputes the allegations. The IPO arrives at a fragile moment for markets amid AI trade turbulence, climbing bond yields, and uncertainty about Federal Reserve interest rate policy.
Read sourceSmart Ring Maker Oura and Investors Plan U.S. IPO of Up to $2.2 Billion
Oura, a Finnish health-focused smart ring manufacturer, along with some of its investors, has filed for an initial public offering (IPO) in the United States, aiming to raise up to $2.2 billion. According to a filing with the U.S. Securities and Exchange Commission on Monday, the company plans to offer 50 million shares at a price range of $40 to $44 per share. The offering consists of 13.5 million shares from the company and 36.5 million shares from existing shareholders. At the top of the price range, the company's market capitalization would be approximately $14.1 billion. This follows a $875 million Series E funding round in 2025 that valued the company at around $11 billion. For the nine months ending June 30, Oura reported revenue of $1.21 billion but a net loss attributable to shareholders of $924.3 million, which includes deemed dividend payments to certain preferred shareholders. The company has sold approximately 3.6 million rings in the past year and has over 5 million paid subscribers. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co, and Jefferies are the lead underwriters for the IPO, which is expected to list on the Nasdaq under the ticker symbol 'OURA'.
Read sourceOura targets $15.62 billion valuation in US IPO, testing fall listing appetite
Smart ring maker Oura is targeting a fully diluted valuation of $15.62 billion in its US initial public offering, as it kicked off its roadshow on Monday. The deal comes amid uncertainty around the AI trade, rising bond yields, and Federal Reserve rate hikes that have kept markets jittery. Oura and some existing investors plan to raise up to $2.2 billion by selling 50 million shares at $40 to $44 each. Weight-loss drugmaker Eli Lilly has indicated interest in buying up to $100 million of the shares, and investment firm Dragoneer has indicated interest in up to $300 million. Oura's revenue surged roughly 74% year-over-year to $1.21 billion in the nine months ended June 30. The company reached a valuation of about $11 billion in a late-stage funding round last year. Samuel Kerr, global head of equity capital markets at Mergermarket, said Oura is the first real test of US appetite after a sluggish September, and a strong debut would encourage other issuers, while a weaker IPO might signal market sentiment is turning. Goldman Sachs, Morgan Stanley, and J.P. Morgan are the lead underwriters. Oura will list on the Nasdaq under the ticker symbol 'OURA'.
Read sourceOura targets $15.62 billion valuation in US IPO, testing investor appetite for fall listings
Oura, the smart ring maker, is targeting a fully diluted valuation of $15.62 billion in its US initial public offering, kicking off its roadshow on Monday. The deal tests investor appetite for consumer technology companies after a slow start to the fall IPO season, amid uncertainty around the AI trade, rising bond yields, and Federal Reserve rate hikes. Oura and some existing investors plan to raise up to $2.2 billion by selling 50 million shares at the top of the indicated price range of $40 to $44. Samuel Kerr, global head of equity capital markets at Mergermarket, said Oura is the first real test of US appetite after a sluggish September and volatile markets, and a strong debut would encourage other issuers, while a weaker IPO might signal turning market sentiment. Weight-loss drugmaker Eli Lilly has indicated interest in purchasing up to $100 million of the shares, and investment firm Dragoneer has indicated interest in buying up to $300 million worth. Oura's revenue surged roughly 74% year-over-year to $1.21 billion in the nine months ended June 30. The company reached a valuation of about $11 billion in a late-stage funding round last year. Goldman Sachs, Morgan Stanley, and J.P. Morgan are the lead underwriters. Oura will list on the Nasdaq under the ticker symbol 'OURA'.